- Home
- NMIH vs CPRX Comparison
NMIH vs CPRX Comparison
Compare NMIH & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMIH | CPRX |
|---|---|---|
| Founded | 2011 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.0B |
| IPO Year | 2013 | 2006 |
Fundamental Metrics
Financial Performance| Metric | NMIH | CPRX |
|---|---|---|
| Price | $37.26 | $22.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $43.00 | $35.00 |
| AVG Volume (30 Days) | 343.9K | ★ 1.0M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.06 | ★ 28.24 |
| EPS | ★ 4.92 | 1.68 |
| Revenue | ★ $706,440,000.00 | $119,072,803.00 |
| Revenue This Year | N/A | $8.00 |
| Revenue Next Year | $4.34 | $9.77 |
| P/E Ratio | ★ $7.56 | $13.58 |
| Revenue Growth | 8.52 | ★ 16.39 |
| 52 Week Low | $32.71 | $19.05 |
| 52 Week High | $43.20 | $26.56 |
Technical Indicators
Market Signals| Indicator | NMIH | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.20 | 39.09 |
| Support Level | $36.78 | $22.25 |
| Resistance Level | $37.66 | $24.94 |
| Average True Range (ATR) | 0.74 | 0.88 |
| MACD | -0.16 | -0.17 |
| Stochastic Oscillator | 25.54 | 17.09 |
Price Performance
Historical ComparisonAbout NMIH NMI Holdings Inc.
NMI Holdings Inc through its subsidiaries provides private mortgage guaranty insurance. The company offers mortgage insurance, reinsurance on loans, and outsourced loan review services to mortgage loan originators. It serves national and regional mortgage banks, money center banks, credit unions, community banks, builder-owned mortgage lenders, Internet-sourced lenders, and other non-bank lenders. It protects lenders and investors from default-related losses on a portion of the unpaid principal balance of a covered mortgage.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.